Cell Analysis Global Market - Forecast to 2029

Abstract
Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is important to understand, predict, and ultimately analyze factors that underlie cell health, proliferation, function, and death by using various technologies such as PCR, Sequencing, Microfluidics, Spectrometry, Microscopes, High content analysis and others. All these technologies play a major role in gene, protein and RNA expression analysis of cells, having application in research, diagnosis and therapeutics development. Continuous advancements in technologies significantly revealed the heterogeneity, which will further enhance the cell analysis application.

According to IQ4I analysis, the cell analysis global market is expected to grow at a low single digit CAGR from 2022 to 2029 to reach $38,020.6 million by 2029. The rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding towards cell based research, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery process are driving the cell analysis market. Growing focus on personalized medicine and the introduction of advanced technologies in cell analysis provides immense opportunities to the cell analysis market. However, stringent government regulations, availability of alternative technologies, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.

The market for cell analysis is segmented based on technique, product, application, end-user and geography. The cell analysis techniques global market is segmented into PCR, Sequencing, Microfluidics and Microarrays, Spectrometry, Microscopy, Cytometry, High Content Analysis, Electrophoresis and Others. Among the techniques, the PCR segment accounted for the largest revenue in 2022. The Sequencing segment is expected to grow at a double digit CAGR from 2022 to 2029.

The cell analysis products market is mainly segmented into consumables, instruments, software and services. Among these, consumables segment commanded the largest revenue in 2022 and is expected to grow at a low single digit CAGR from 2022 to 2029. The software and services segment is expected to grow at a mid single digit CAGR from 2022 to 2029.

The consumables market is further sub-segmented into reagents, assay kits, microplates and others. Among the consumables sub-segments, the assay kits held the largest revenue in 2022. Reagents sub-segment is the fastest growing segment with a mid single digit CAGR from 2022 to 2029.

The instrument segment is further classified into cell counters, cell microarray and microfluidics, liquid handling systems, cytometers, microfluidic devices, high content screening (HCS) systems, microplate readers, PCR devices, sequencing instruments, spectrometer, microscopes and others. Among the instruments, the PCR instruments is commanded the largest revenue of in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029 to reach $xx million by 2029. Cell Microarrays and Microfluidics are expected to grow at a low single digit CAGR of from 2022 to 2029 due to increasing advancements in microfluidic technologies mainly for single-cell analysis applications.

The application market is categorized based on processes, field, and by therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening. Cellular process application accounted for the largest revenue in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029. The single-cell analysis market is expected to boom at a high single digit CAGR from 2022 to 2029 due to increasing advancement in single-cell technologies. Based on field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics.

Diagnostics held the largest revenue of in 2022. Stem cell analysis is the fastest-growing segment at a mid single digit from 2022 to 2029. The cell imaging market is further segmented into live-cell imaging which commanded revenue of $xx million in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Based on therapeutic area, the market is further segmented into cancer, infectious disease, genetic testing, immunology, and others. The Infectious diseases accounted for the largest revenue in 2022. Cancer is the fastest-growing segment with a mid single digit CAGR from 2022 to 2029.

The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others. Hospitals & Diagnostic laboratories generated the largest revenue in 2022. Academic and research laboratories are expected to grow at a mid single digit CAGR from 2022 to 2029.

Based on geography, the cell analysis global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K. and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR from 2022 to 2029. The factors such as increasing R&D expenditure, increasing incidence of infectious and non-infectious disease, increasing government funding towards the therapeutic and diagnostic research, presence of major players, increasing scope for the cell analysis application in drug discovery, increasing interest towards personalized medicine and development of the innovative platform for high growth potential single-cell analysis application are driving the market.

The Asia-Pacific is the fastest-growing region in the cell analysis global market with a revenue of $xx million in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR from 2022 to 2029 which is attributed to the increased scope for research activities in academic & research institutes, increasing outsourcing, increased incidence of chronic diseases (cancer) and infectious disease, increasing awareness about early screening (cancer) and prenatal test and their adoption in clinical care, increasing government and private investment for - cell-based research and also for the development & expansion single-cell analysis technologies and increasing number startup companies engaged in the development innovative solutions. However, lack of technical expertise, high cost of instruments, lack of skilled labors, and large scale clinical data challenges are some of the restraints for the cell analysis market in the region.

The cell analysis global market is competitive and all the players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the cell analysis global market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Illumina Inc. (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Thermo Fisher Scientific, Inc. (U.S.), Roche Holdings, Inc. (Switzerland), Abbott Laboratories (U.S.) and 10X Genomics (U.S.)

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
North America
U.S.
Rest of North America
Europe
Germany
U.K.
France
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of APAC
Rest of the World (Row)
Brazil
Rest of LATAM
The Middle East and Africa

Content
Table of Contents

1 EXECUTIVE SUMMARY 27
2 INTRODUCTION 37
2.1 KEY TAKEAWAYS 37
2.2 SCOPE OF THE REPORT 38
2.3 REPORT DESCRIPTION 38
2.4 MARKETS COVERED 42
2.5 STAKEHOLDERS 44
2.6 RESEARCH METHODOLOGY 45
2.6.1 MARKET SIZE ESTIMATION 47
2.6.2 MARKET BREAKDOWN & DATA TRIANGULATION 50
2.6.3 SECONDARY SOURCES 51
2.6.4 KEY DATA POINTS FROM SECONDARY SOURCES 52
2.6.5 PRIMARY SOURCES 53
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 53
2.6.7 ASSUMPTIONS 54
3 MARKET ANALYSIS 56
3.1 INTRODUCTION 56
3.2 MARKET SEGMENTATION 57
3.3 FACTORS INFLUENCING MARKET 60
3.3.1 DRIVERS AND OPPORTUNITIES 61
3.3.1.1 Rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment 61
3.3.1.2 Increasing government and private funding 63
3.3.1.3 Increasing advancements in cell imaging technologies reduce the cost and time consumption for the drug discovery process 65
3.3.1.4 Growing focus on personalized medicine 67
3.3.1.5 Introduction of advanced technologies in cell analysis 69
3.3.1.6 Increasing merger and acquisition activities in cell analysis 72
3.3.2 RESTRAINTS & THREATS 73
3.3.2.1 Lack of skilled personnel to use advanced cell analysis instruments 73
3.3.2.2 Expensive cell analysis instruments 74
3.3.2.3 Maintaining consistency, reproducibility of assays and lack of standardization 75
3.3.2.4 Avalbility of alternative technlogies 76
3.3.2.5 Stringent regulatory framework limits advancements in cellular analysis market 77
3.4 REGULATORY AFFAIRS 78
3.4.1 U.S. 78
3.4.2 EUROPE 79
3.4.3 CHINA 80
3.4.4 INDIA 80
3.4.5 JAPAN 81
3.5 FUNDING SCENARIO 82
3.6 CELL ANALYSIS – DEALS, AND NEW PRODUCT LAUNCH 98
3.7 TECHNOLOGICAL ADVANCEMENTS 124
3.7.1 INTRODUCTION 124
3.7.2 CRISPER LIVE CELL IMAGING 124
3.7.3 SINGLE-CELL MULTI-OMICS 125
3.7.4 RAMAN LIVE CELL IMAGING 127
3.7.5 DROPLET-BASED MICROFLUIDICS IN SINGLE-CELL ANALYSIS 128
3.7.6 INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY IN SINGLE-CELL ANALYSIS (ICP-MS) 129
3.7.7 DEEP LEARNING AND AI IN MICROSCOPY 131
3.7.8 INTELLIGENT IMAGE-ACTIVATED CELL SORTING OR AI-DRIVEN CELL ISOLATION TECHNOLOGY 131
3.7.9 ADVANCED SPATIAL TECHNOLOGIES IN CELL ANALYSIS 132
3.7.10 DIGITAL MICROFLUIDIC ISOLATION OF SINGLE-CELLS FOR -OMICS (DISCO) 134
3.8 IMPACT OF COVID-19 ON CELL ANALYSIS MARKET 135
3.9 PORTER’S FIVE FORCE ANALYSIS 137
3.9.1 THREAT OF NEW ENTRANTS 138
3.9.2 THREAT OF SUBSTITUTES 140
3.9.3 COMPETITIVE RIVALRY 141
3.9.4 BARGAINING POWER OF SUPPLIERS 143
3.9.5 BARGAINING POWER OF BUYERS 144
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 145
3.10.1 CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS 145
3.10.2 MARKET SHARE ANALYSIS BY SINGLE-CELL ANALYSIS MAJOR PLAYERS 151
3.11 COMPANY MATRIX ANALYSIS 155
4 CELL ANALYSIS GLOBAL MARKET, BASED ON TECHNIQUES 160
4.1 INTRODUCTION 160
4.1.1 PCR (POLYMERASE CHAIN REACTION) 163
4.1.2 SEQUENCING 167
4.1.3 MICROFLUIDICS AND MICROARRAYS 170
4.1.4 SPECTROMETRY 175
4.1.5 MICROSCOPY 180
4.1.6 CYTOMETRY 189
4.1.7 HIGH CONTENT SCREENING 195
4.1.8 ELECTROPHORESIS 198
4.1.9 OTHERS 201
5 CELL ANALYSIS GLOBAL MARKET, BASED ON PRODUCTS 207
5.1 INTRODUCTION 207
5.2 CONSUMABLES 210
5.2.1 ASSAY KITS 212
5.2.2 REAGENTS 219
5.2.3 MICROPLATES 221
5.2.4 OTHERS 223
5.3 INSTRUMENTS 224
5.3.1 CELL COUNTERS 228
5.3.2 CELL MICROARRAYS AND MICROFLUIDICS 231
5.3.3 LIQUID HANDLING SYSTEMS 234
5.3.4 CYTOMETERS 236
5.3.5 HIGH CONTENT SCREENING SYSTEMS 239
5.3.6 MICROPLATE READERS 241
5.3.7 PCR INSTRUMENTS 243
5.3.8 SEQUENCING INSTRUMENTS 250
5.3.9 SPECTROMETERS 253
5.3.10 MICROSCOPES 255
5.3.11 OTHER INSTRUMENTS 257
5.4 SOFTWARE AND SERVICES 258
6 CELL ANALYSIS GLOBAL MARKET, BASED ON APPLICATION 263
6.1 INTRODUCTION 263
6.2 CELL ANALYSIS GLOBAL MARKET, BASED ON THE PROCESS OF
APPLICATION 265
6.2.1 CELLULAR PROCESSES 267
6.2.2 SIGNAL TRANSDUCTION PATHWAY 270
6.2.3 CIRCULATING TUMOR CELLS 273
6.2.4 SINGLE-CELL ANALYSIS 282
6.2.5 EPIGENETIC TARGET ANALYSIS 290
6.2.6 SUBPOPULATION CHARACTERIZATION 292
6.2.7 DRUG AND CANDIDATE SCREENING 295
6.3 CELL ANALYSIS GLOBAL MARKET, BASED ON THE FIELD OF APPLICATION 299
6.3.1 FORENSICS 302
6.3.2 THERAPEUTICS 305
6.3.3 GENOMIC ANALYSIS 308
6.3.4 STEM CELL ANALYSIS 312
6.3.5 BIOMARKER RESEARCH 315
6.3.6 CELL IMAGING 318
6.3.6.1 LIVE-CELL IMAGING 320
6.3.7 DIAGNOSTICS 323
6.4 CELL ANALYSIS GLOBAL MARKET, BASED ON THERAPEUTIC AREA OF APPLICATIONS 330
6.4.1 CANCER 333
6.4.2 GENETIC TESTING 337
6.4.3 INFECTIOUS DISEASES 338
6.4.4 IMMUNOLOGY 343
6.4.5 OTHERS 346
7 CELL ANALYSIS GLOBAL MARKET, BASED ON END-USERS 349
7.1 INTRODUCTION 349
7.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 352
7.3 ACADEMIC & RESEARCH LABORATORIES 354
7.4 PHARMACEUTICALS AND BIOTECH COMPANIES 356
7.5 CONTRACT RESEARCH ORGANISATIONS 359
7.6 CELL BANKS 361
7.7 OTHERS 363
8 REGIONAL MARKET ANALYSIS 365
8.1 INTRODUCTION 365
8.2 NORTH AMERICA 370
8.2.1 UNITED STATES (U.S.) 390
8.2.2 REST OF NORTH AMERICA 397
8.3 EUROPE 402
8.3.1 GERMANY 422
8.3.2 FRANCE 427
8.3.3 U.K. 433
8.3.4 REST OF EUROPE 437
8.4 ASIA PACIFIC 442
8.4.1 JAPAN 461
8.4.2 CHINA 466
8.4.3 INDIA 471
8.4.4 REST OF APAC 476
8.5 REST OF THE WORLD 480
8.5.1 BRAZIL 499
8.5.2 REST OF LATIN AMERICA 504
8.5.3 MIDDLE EAST AND AFRICA 508
9 COMPETITIVE LANDSCAPE 513
9.1 INTRODUCTION 513
9.2 NEW PRODUCT LAUNCH 514
9.3 APPROVAL 528
9.4 AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS 538
9.5 ACQUISITIONS 542
9.6 EXPANSION 544
10 MAJOR PLAYER PROFILES 546
10.1 10X GENOMICS, INC. 546
10.1.1 OVERVIEW 546
10.1.2 FINANCIALS 547
10.1.3 PRODUCT PORTFOLIO 549
10.1.4 KEY DEVELOPMENTS 556
10.1.5 BUSINESS STRATEGY 558
10.1.6 SWOT ANALYSIS 559
10.2 ABBOTT LABORATORIES, INC 560
10.2.1 OVERVIEW 560
10.2.2 FINANCIALS 561
10.2.3 PRODUCT PORTFOLIO 564
10.2.4 KEY DEVELOPMENTS 565
10.2.5 BUSINESS STRATEGY 566
10.2.6 SWOT ANALYSIS 567
10.3 AGILENT TECHNOLOGIES, INC. 568
10.3.1 OVERVIEW 568
10.3.2 FINANCIALS 569
10.3.3 PRODUCT PORTFOLIO 571
10.3.4 KEY DEVELOPMENTS 582
10.3.5 BUSINESS STRATEGY 586
10.3.6 SWOT ANALYSIS 587
10.4 BECTON DICKINSON AND COMPANY 588
10.4.1 OVERVIEW 588
10.4.2 FINANCIALS 589
10.4.3 PRODUCT PORTFOLIO 592
10.4.4 KEY DEVELOPMENTS 595
10.4.5 BUSINESS STRATEGY 597
10.4.6 SWOT ANALYSIS 599
10.5 BIO-RAD LABORATORIES, INC 600
10.5.1 OVERVIEW 600
10.5.2 FINANCIALS 601
10.5.3 PRODUCT PORTFOLIO 603
10.5.4 KEY DEVELOPMENTS 608
10.5.5 BUSINESS STRATEGY 612
10.5.6 SWOT ANALYSIS 613
10.6 DANAHER CORPORATION 614
10.6.1 OVERVIEW 614
10.6.2 FINANCIALS 615
10.6.3 PRODUCT PORTFOLIO 617
10.6.4 KEY DEVELOPMENTS 624
10.6.5 BUSINESS STRATEGY. 628
10.6.6 SWOT ANALYSIS 629
10.7 F.HOFFMANN-LA ROCHE LTD 630
10.7.1 OVERVIEW 630
10.7.2 FINANCIALS 631
10.7.3 PRODUCT PORTFOLIO 634
10.7.4 KEY DEVELOPMENTS 639
10.7.5 BUSINESS STRATEGY 644
10.7.6 SWOT ANALYSIS 645
10.8 ILLUMINA, INC. 646
10.8.1 OVERVIEW 646
10.8.2 FINANCIALS 647
10.8.3 PRODUCT PORTFOLIO 649
10.8.4 KEY DEVELOPMENTS 651
10.8.5 BUSINESS STRATEGY 654
10.8.6 SWOT ANALYSIS 655
10.9 MERCK KGAA 656
10.9.1 OVERVIEW 656
10.9.2 FINANCIALS 657
10.9.3 PRODUCT PORTFOLIO 660
10.9.4 KEY DEVELOPMENTS 665
10.9.5 BUSINESS STRATEGY 666
10.9.6 SWOT ANALYSIS 667
10.10 PERKINELMER, INC. 668
10.10.1 OVERVIEW 668
10.10.2 FINANCIALS 669
10.10.3 PRODUCT PORTFOLIO 671
10.10.4 KEY DEVELOPMENTS 675
10.10.5 BUSINESS STRATEGY 677
10.10.6 SWOT ANALYSIS 678
10.11 QIAGEN N.V 679
10.11.1 OVERVIEW 679
10.11.2 FINANCIALS 680
10.11.3 PRODUCT PORTFOLIO 682
10.11.4 KEY DEVELOPMENTS 686
10.11.5 BUSINESS STRATEGY 688
10.11.6 SWOT ANALYSIS 689
10.12 THERMO FISHER SCIENTIFIC, INC. 690
10.12.1 OVERVIEW 690
10.12.2 FINANCIALS 691
10.12.3 PRODUCT PORTFOLIO 693
10.12.4 KEY DEVELOPMENTS 699
10.12.5 BUSINESS STRATEGY 705
10.12.6 SWOT ANALYSIS 708